TherapeuticsMD Q2 net income $112.3M; revenue $28.6M (+24% YoY); ANNOVERA sales double

TherapeuticsMD, Inc.

2022-Q2 EPS reported $7.05 revenue$47,894,000

Net revenue $28.6M, up 24% YoY; net income $112.3M ($12.83 basic EPS) vs net loss $42.7M in Q2 2021.
ANNOVERA revenue $18.3M, up 91% YoY; 9,329 TRx (+28% YoY); over 13,000 prescribing HCPs (+65%).
Operating expenses fell 21% to $42.7M; debt reduced to $90.8M after repaying $125M in 2022.
Cash $26.3M plus $11.3M restricted; vitaCare divestiture gain $143.4M.
FDA approved sNDA for ANNOVERA; CEO highlights focus on women's health.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.